Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Rx Compliance Programs May Be Undermined By Federal Investigations

Executive Summary

Federal investigators' increasing use of information gathered through internal investigations may undermine the effectiveness of corporate compliance programs, attorney Steven Kowal of Bell Boyd & Lloyd (Chicago) said

You may also be interested in...

Rx Promotion Spending Limits Required By California Compliance Law

A California law scheduled to take effect July 1 will challenge the pharmaceutical industry's ability to track promotional spending

Compliance Officers Make Good “Whistleblowers” – U.S. Prosecutor Sheehan

Corporate compliance officers will make up the next wave of "whistleblowers" in health care fraud cases, Philadelphia Associate U.S. Attorney James Sheehan said at the Food & Drug Law Institute Enforcement & Litigation Conference in Washington, D.C. Sept. 22

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts